Core Points - Junshi Bioscience's stock price has increased by 42.01% year-to-date but has seen a decline of 5.34% in the last five trading days and 19.15% over the past 20 days [2] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, an increase of 36.01% year-on-year [2] Company Overview - Junshi Bioscience, established on December 27, 2012, and listed on July 15, 2020, is located in Shanghai and focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The company's main revenue sources include drug sales (90.67%), technology licensing and royalties (8.74%), and technical services and others (0.59%) [2] Market Activity - As of October 13, Junshi Bioscience's stock was trading at 38.81 yuan per share, with a market capitalization of 39.846 billion yuan [1] - The stock experienced a net outflow of 12.9063 million yuan in principal funds, with large orders showing a buy of 30.8144 million yuan and a sell of 43.5137 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders for Junshi Bioscience was 31,200, an increase of 5.88% from the previous period, with an average of 24,543 circulating shares per person, a decrease of 5.56% [2] - The top ten circulating shareholders include various ETFs, with notable changes in holdings, such as a decrease of 536,700 shares for 华夏上证科创板50成份ETF and an increase of 630,000 shares for 易方达上证科创板50ETF [3]

Core Viewpoint - The controlling shareholder and chairman of Shanghai Junshi Biosciences Co., Ltd., Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB 100 million over the next 12 months, with a minimum of RMB 50 million allocated for A-shares [2]. Group 1: Shareholding Increase Plan - Mr. Xiong intends to start the share purchase from April 12, 2025, using methods permitted by the Shanghai Stock Exchange and Hong Kong Stock Exchange, including but not limited to centralized bidding and block trading [2]. - As of October 11, 2025, the share purchase plan is more than halfway through, but Mr. Xiong has not yet made any purchases due to factors such as reporting windows, equity incentive matters, and funding arrangements [5]. - The plan remains unfulfilled, and Mr. Xiong will continue to seek opportunities to increase his shareholding during the implementation period [5]. Group 2: Shareholding Details - Mr. Xiong directly holds 87,856,618 shares in the company, which includes 87,854,018 A-shares and 2,600 H-shares, with the latter held by HKSCC NOMINEES LIMITED as a nominal holder [3]. - The shareholding percentage is calculated based on the company's total share capital of 1,026,689,871 shares [3][4]. Group 3: Risk Factors - The share purchase plan may face risks due to changes in capital market conditions or other unpredictable factors that could prevent the plan from achieving its intended outcomes [6][8]. - The implementation of the share purchase plan will not lead to changes in the company's controlling shareholder or actual controller [7].

Investment Rating - The report rates the industry as "Overweight" [4] Core Insights - The siRNA drug industry is entering a new era with the maturation of technology platforms and the expansion of indications, focusing on the commercial value of siRNA drugs for common diseases [2][3] - siRNA drugs have transitioned from rare diseases to common diseases, showcasing strong target expansion capabilities, robust research and development extensibility, long-lasting effects, and low resistance [4][12] - The industry is witnessing a surge in business development (BD) transactions, particularly among multinational corporations (MNCs), indicating a vibrant market for siRNA technology [4][31] Summary by Sections 1. Dawn of a New Era for Small Nucleic Acid Drugs - Small nucleic acid drugs, including siRNA and ASO, are becoming a significant path for drug development, with a focus on their ability to regulate protein production [7] - The global approval of small nucleic acid drugs has reached 23, with siRNA drugs leading the way in rare disease applications [12][13] - Alnylam and other leading companies have demonstrated significant market capitalization differences due to their innovative drug development technologies [14][16] 2. Platform Characteristics and Focus on Indications - The siRNA drug industry is characterized by high barriers in modification and delivery, with a focus on breakthroughs in extrahepatic delivery systems [6][29] - The commercialization of siRNA drugs is accelerating, with multiple common diseases nearing market readiness [6][29] - The GalNAc delivery system has become the mainstream strategy for liver-targeted siRNA delivery, while breakthroughs in extrahepatic delivery are still needed [6][29] 3. Related Companies - Listed companies in the siRNA space include Yuyuan Pharmaceutical, Hengrui Medicine, and others, while unlisted companies include Bewang Pharmaceutical and others [4][12]

Core Viewpoint - Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months starting from April 12, 2025, with a minimum of RMB 50 million allocated for A-shares [1] Group 1 - Mr. Xiong Jun intends to acquire shares through the Shanghai Stock Exchange and Hong Kong Stock Exchange, utilizing methods such as centralized bidding and block trading [1] - As of October 11, 2025, the share acquisition plan is more than halfway through, but Mr. Xiong has not yet made any purchases due to factors such as reporting periods, equity incentive matters, and funding arrangements [1] - The acquisition plan remains unfulfilled, and Mr. Xiong will continue to seek opportunities to increase his stake during the implementation period [1]

Core Viewpoint - The chairman of Junshi Biosciences, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025, with a minimum of RMB 50 million allocated for A-shares [1] Group 1 - Mr. Xiong Jun has not yet executed the share purchase plan due to various factors including reporting periods, equity incentive matters, and funding arrangements [1] - The share purchase plan is still ongoing, and Mr. Xiong intends to proceed with the acquisition of shares during the implementation period [1] - The plan may face risks due to changes in capital market conditions or other unpredictable factors that could hinder the expected outcomes of the share purchase [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於控股股東、實際控制人之一兼董事長增持股 份進展暨增持時間過半公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年10月10日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 本公司董事会、全体董事及相关股东保证本公告 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-061 上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展暨增持时间过半公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： | 增持主体名称 | 熊俊 | | | | --- | --- | --- | --- | | 增持主体身份 | 控股股东、实控人 | 是 | 否 | | | 控股股东、实控人的一致行动人 | 是 | 否 | | | 直接持股 5%以上股东 | 是 | 否 | | | 董事、监事和高级管理人员 | 是 | 否 | | | 其他：__________ | | | 一、增持主体的基本情况 | 增持前持股比例 | | | --- | --- | | 增持前持股数量 （占总股本） | 87,856,618 股 8.56% | 注 1：熊俊先生直接持有公司股份 87,856,618 股（包含 87,854,018 股 A 股和 2,600 股 H 股，其中由 HK ...

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

Core Viewpoint - The Hong Kong biopharmaceutical stocks continued to decline, with significant drops in several key companies, indicating a bearish trend in the sector [1]. Group 1: Stock Performance - Innovent Biologics (09969) experienced a decline of 11.19%, with a latest price of 14.760 and a total market capitalization of 26.021 billion, despite a year-to-date increase of 141.18% [2]. - Rongchang Biologics (09995) fell by 10.22%, with a latest price of 95.350 and a market cap of 53.747 billion, showing a remarkable year-to-date increase of 562.15% [2]. - WuXi AppTec (02268) saw a decrease of 5.68%, with a latest price of 73.100 and a market cap of 89.818 billion, maintaining a year-to-date increase of 138.50% [2]. - WuXi Biologics (02269) dropped by 5.32%, with a latest price of 38.780 and a market cap of 158.528 billion, reflecting a year-to-date increase of 120.84% [2]. - Fuhong Hanlin (02696) declined by 4.42%, with a latest price of 72.400 and a market cap of 39.349 billion, showing a year-to-date increase of 205.49% [2]. - Kelun-Biotech (06990) decreased by 4.25%, with a latest price of 488.800 and a market cap of 113.981 billion, with a year-to-date increase of 199.33% [2]. - WuXi AppTec (02359) fell by 4.19%, with a latest price of 114.400 and a market cap of 339.275 billion, reflecting a year-to-date increase of 109.21% [2]. - Gendicine (09688) saw a decrease of 2.83%, with a latest price of 25.440 and a market cap of 28.432 billion, with a year-to-date increase of 21.72% [2]. - CanSino Biologics (09926) declined by 2.05%, with a latest price of 128.800 and a market cap of 118.643 billion, reflecting a year-to-date increase of 112.19% [2]. - Junshi Biosciences (01877) fell by 2.02%, with a latest price of 29.100 and a market cap of 29.877 billion, showing a year-to-date increase of 151.30% [2].

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Junshi Biosciences, indicating a significant level of financing and margin trading activity, suggesting investor interest and potential volatility in the stock [1][2][3] Group 2 - As of October 9, Junshi Biosciences experienced a trading decline of 0.96% with a transaction volume of 488 million yuan, and a net financing purchase of 11.61 million yuan [1] - The total financing and margin trading balance for Junshi Biosciences reached 1.4 billion yuan, with the financing balance accounting for 4.43% of the circulating market value, indicating a high level of leverage compared to the past year [1] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, reflecting a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a 36.01% increase in losses compared to the previous period [2]